糖尿病合并血脂异常患者的用药选择

2021-07-21 河北省人民医院宋光耀教授访谈 MedSci原创

多项临床研究结果都显示,津力达颗粒具有调节糖脂代谢的独特优势,与常规西药联用,能为糖尿病合并血脂异常患者带来更多获益。

     

      第十七届国际络病学大会糖尿病论坛上,河北省人民医院的宋光耀教授和医学界同仁们分享了糖尿病及其并发症在治疗过程中联合或单用中医药治疗糖尿病,特别是糖尿病血管并发症的一些研究所获为中西医治疗糖尿病以及血脂异常导致的并发症提供了更多思路梅斯医学也借本次论坛机会与宋光耀教授做了一次深度交流。

 

河北省人民医院宋光耀教授

       

       糖尿病及其并发症在临床工作中的难点

      据最新调查显示,2017年中国成年人糖尿病患病率高达11.2%,估计患病人数为1.298亿,约占全球糖尿病患者总数的1/4。糖尿病并发症发病率持续升高,而血糖控制率仍较低。宋光耀教授认为在实际临床上,治疗糖尿病及其并发症时对患者的用药管理难度大,部分病患治疗的效果并不乐观。

 

      就现阶段临床治疗使用的药品而言,品种、剂型相对全面,不过由于糖尿病发病原因复杂,所以病患在进行中西医联合用药时的情况也很复杂,例如有的药品需要餐前服用,有的需要餐后服用,有的需要注射,多种并发症的患者为了达到治疗效果还需要同时服用多种药物进行治疗,这给病患在经济和心理上都带来了压力。

 

      血糖和糖化血红蛋白达标是判断治疗方案和治疗药物是否有效的重要标准之一,英国前瞻性糖尿病研究(UKPDS)的流行病学分析证明,糖化血红蛋白HbA1C水平每增加1个百分点,就会使微血管或大血管并发症的危险性升高37%。作为糖尿病治疗达标的“金标准”,糖化血红蛋白HbA1C的监测是糖尿病治疗措施中的重要环节。目前推荐糖尿病患者每3个月监测一次HbA1C。自2005年以来,IDF和DF-WPR颁布的糖尿病指南中,都将HbA1C的控制目标从7%降至6.5%。这一更严格的血糖控制目标,为糖尿病治疗带来了更为严峻的挑战。

 

      宋光耀教授与同仁们分享了一项14万余患者参与的糖尿病调查研究。该调查研究的样本量足够大,治疗中病患使用的药物种类涵盖全面。调查结果显示,受访者的临床治疗达标率不足50%,特别是治疗中使用胰岛素注射药物的病患,治疗达标率反而低。这也进一步验证了对糖尿病血糖和糖化血红蛋白以及并发症控制的难度。

 

      中西医联合治疗糖尿病的优势

      糖尿病是由于体内胰岛素不足,引起糖、脂肪、蛋白质的代谢紊乱,从而导致的一组内分泌代谢综合病症。伴随着糖尿病病程延长,可伴发眼、神经及心、脑、肾等血管组织器官的慢性并发症,此为糖尿病致残致死的主要因素。脂代谢异常与糖尿病及其血管并发症一直是宋光耀教授临床研究的方向,这类病患在临床治疗及用药管理中情况复杂。

 

      糖尿病属中医的“消渴”范畴。宋光耀教授谈到中医药对糖尿病的贡献有几千年的历史,优势明确。资料表明,中医辨证论治糖尿病的方剂也不少。宋光耀教授在十多年前注意到中医药对糖尿病以及并发症治疗具有一定优势。于是,开始用现代科学的论点、论据,对中药治疗这类疾病进行研究。

 

      宋光耀教授介绍,临床早期用中药干预治疗,可以延缓或减轻并发症。中西医结合治疗糖尿病,在对血糖和糖化血红蛋白指标进行严格控制的同时,又可以对脏器功能进行调理和改善,能够更好地控制血糖,维持糖化血红蛋白达标,还可以阻止和延缓并发症的发生,在一定程度上减轻患者的经济压力。

 

      津力达颗粒调节糖脂代谢,改善胰岛素抵抗

      宋光耀教授介绍津力达颗粒在十多前就开始应用于临床,当时在一些文献中看到其治疗效果后,宋光耀教授和课题组针对津力达颗粒的作用机制开始了系列的基础研究。

 

      宋光耀教授谈到他们有课题组一直在做津力达颗粒改善糖脂代谢与胰岛素抵抗方面的研究。为了进一步明确津力达颗粒调糖降脂的功效,宋光耀教授所在的课题组进行了津力达颗粒改善高脂饮食诱导的大鼠胰岛素抵抗的作用机制的研究,课题主要从改善骨骼肌脂质沉积角度探讨中成药津力达颗粒改善大鼠胰岛素抵抗的分子机制。课题组将雄性SD大鼠随机分为正常饮食组和高脂喂养组,进行胰岛素抵抗造模。造模成功后,高脂饮食组又分为高脂对照组,津力达低、中、高剂量治疗组,阳性对照吡格列酮/二甲双胍治疗组。研究发现,津力达颗粒干预不但能够改善血液中的血脂水平,还能降低骨骼肌和肝脏内的脂质的沉积,降低肝脏氧化应激。

 

     课题组在第二部分做了细胞实验,分为两种,一种是肝脏细胞,一种是成肌细胞。肝细胞用棕榈酸做胰岛素抵抗模型,研究结果发现津力达可以提高AKT和PI3K磷酸化水平,恢复胰岛素信号通路,改善细胞的胰岛素抵抗、增加肝细胞对胰岛素的敏感性,加强脂肪酸和蛋白的利用。成肌细胞也用棕榈酸进行胰岛素抵抗造模。研究发现,津力达可以通过促进AMPK的磷酸化使其激活,进而作用于下游信号通路,促进脂肪酸及葡萄糖的利用,改善肌细胞的脂质沉积。

 

      宋光耀教授表示,这些基础研究表明,津力达颗粒可有效改善高脂诱导的胰岛素抵抗和血脂升高,其作用机制是多靶点的,治疗效果是多效应的。宋光耀教授介绍,既往多项临床研究显示,津力达颗粒配合西药一起服用,效果明显优于单独服用西药。

 

      今年上半年,《中华糖尿病杂志》全文刊登了中华医学会糖尿病学分会(CDS)发布的《中国2型糖尿病防治指南(2020年版)》(以下简称“新版指南”)。新版指南更加强调中医药的诊治经验及数据,进一步明确了中医药在糖尿病防治中的重要地位和作用。

 

     《新版指南》指出,津力达颗粒能够改善胰岛功能和胰岛抵抗、降低糖化血红蛋白、减轻体重、改善症状。因此,推荐2型糖尿患者在应用二甲双胍等降糖药物的基础上加服津力达颗粒。这是继《中国2型糖尿病防治指南(2017年版)》首次纳入中医药章节即获推荐后,中医络病理论指导研发的创新中药津力达颗粒再次入选新版指南,充分体现出津力达颗粒在2型糖尿病临床治疗中的重要作用,同时进一步彰显了中医络病理论在糖尿病防治领域的学术价值。

 

     基于津力达颗粒在糖尿病防治中的显著疗效,其已先后被《国际中医药糖尿病诊疗指南》《糖尿病周围神经病变中医临床诊疗指南》《糖尿病中医药临床循证实践指南》《中成药临床应用指南-糖尿病分册》《中国2型糖尿病诊疗标准》(2019英文版)《糖尿病微循环障碍临床用药专家共识》《中医临床辨治》等多部指南、共识、教材列为推荐用药。此外,“以津力达颗粒为示范的中西医联合应用的规范化研究”荣获2019年中华中医药学会科学技术二等奖。

 

      除上述研究外,多项临床研究结果都显示,津力达颗粒具有调节糖脂代谢的独特优势,与常规西药联用,能为糖尿病合并血脂异常患者带来更多获益。

 

 

专家简介:内分泌科主任医师、教授、博士研究生导师,河北内分泌代谢病研究所所长;河北内分泌代谢病诊疗中心主任;享受国务院特殊津贴专家。

医疗专长:内分泌代谢科。

研究方向:主要研究脂代谢与糖尿病及其血管并发症。

 

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-11-30 ms3000000253959076

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-11-07 ms1000000251410274

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-08-22 ms4000001678904427

    中药

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-08-21 开心小屋

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-08-04 小小的丁香花

    中医药前景可观

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-07-21 王旭锋

    #学习#嘿嘿嘿

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-07-21 王旭锋

    其实

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-07-21 ms7000000999069956

    学习了,很实用的干货

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1075513, encodeId=1ee810e551349, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6b35722778, createdName=ms3000000253959076, createdTime=Tue Nov 30 19:00:28 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067794, encodeId=affb106e794e3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Sun Nov 07 14:30:57 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010319, encodeId=1f2a1010319a2, content=中药, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f3b5467681, createdName=ms4000001678904427, createdTime=Sun Aug 22 15:34:20 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010081, encodeId=3e63101008156, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0aa5440770, createdName=开心小屋, createdTime=Sat Aug 21 16:54:19 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005029, encodeId=7a201005029bf, content=中医药前景可观, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210804/5785b262ac614e2787c8b09e8d8ae840/5cf1162cd10d42bc817ae4b32662d7f8.jpg, createdBy=c27d4938136, createdName=小小的丁香花, createdTime=Wed Aug 04 06:13:04 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253791, encodeId=524d1253e91be, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 23 07:51:23 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001518, encodeId=0c2e1001518df, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嘿嘿嘿, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:39 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001517, encodeId=0e6c100151ec9, content=其实, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3d5549193, createdName=王旭锋, createdTime=Wed Jul 21 22:11:29 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001505, encodeId=95fc100150570, content=学习了,很实用的干货, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54465431888, createdName=ms7000000999069956, createdTime=Wed Jul 21 21:41:46 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043700, encodeId=00661043e0074, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jul 21 19:51:23 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-07-21 misszhang

    谢谢MedSci提供最新的资讯

    0